Prevalence of dyslipidemic phenotypes including hyper-apoB and evaluation of cardiovascular disease risk in normocholesterolemic type 2 diabetic patients

Pakistan Journal of Biological Sciences

Volumn 9, Issue 8, 2006, Pages 1536-1541

  Shekhar, Hossain Uddin ^a   Shahjalal, Hussain Md ^b   Ahmed, Rumana ^a   Uddin, Mesbah ^c   Kaniz Khatun E Jannath, ^d  

^a UNIVERSITY OF DHAKA   (Bangladesh)

^b JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

^c Popular Diagnostic Centre   (Bangladesh)

^d Greenland Hospital   (Bangladesh)

Author keywords

Apolipoprotein B; Hyperlipidemia; Type 2 Diabetes

Indexed keywords

EID: 33749667947     PISSN: 10288880     EISSN: 18125735     Source Type: Journal    
DOI: 10.3923/pjbs.2006.1536.1541     Document Type: Article

References (25)

1. Assmann, G. and H. Schulte, 1988. The Prospective Cardiovascular Munster (PROCAM) Study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart J., 116: 1713-1724.
2. Austin, M.A., 1999. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am. J. Cardiol., 83: 13F-16F.
3. Brown, M.S. and J.L. Goldstein, 1986. A receptor-mediated pathway for cholesterol homeostasis. Science, 232: 34-47.
4. Contois, J.H., J.R. McNamara, C.J. Lammi-Keefe, P.W. Wilson, T. Massov and E.J. Schaefer, 1996. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham offspring study. Clin. Chem., 42: 515-523.
5. Cummings, M.H., G.F. Watts, A.M. Umpleby, T.R. Hennessy, R. Naoumova, B.M. Slavin, G.R. Thompson and P.H. Sonksen, 1995. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia, 38: 959-967.
6. Elovson, J., J.E. Chatterton, G.T. Bell, V.N. Schumaker, M.A. Reuben, D.L. Puppione, J.R. Reeve and N.L. Young, 1988. Plasma very low-density lipoproteins contain a single molecule of apolipoprotein B. J. Lipid Res., 29: 1461-73.
7. Gotto, A.M., 1998. Triglyceride: The forgotten risk factor [Editorial]. Circulation, 97: 1027-1028.
8. Haffner, S.M., 1998. Management of dyslipidemia in adults with diabetes. Diabetes Care, 21: 160-178.
9. Isomaa, B., P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M.R. Taskinen and L. Groop, 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24: 683-689.
10. Kannel, W.B., 1985. Lipids, diabetes and coronary heart disease: Insights from the Framingham Study. Am. Heart J., 110: 1100-1107.
11. Kwiterovich, P.O., J. Coresh and P.S. Bachorik, 1993. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (< or = 60 years) with coronary artery disease. Am. J. Cardiol., 71: 631-639.
12. Lamarche, B., J.P. Despres, S. Moorjani, B. Cantin, G.R. Dagenais and P.J. Lupien, 1995. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am. J. Cardiol., 75: 1189-1195.
13. Lamarche, B., S. Moorjani, P.J. Lupien, B. Cantin, P.M. Bernard, G.R. Dagenais and J.P. Despres, 1996. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation, 94: 273-278.
14. Lamarche, B., A. Tchernof, S. Moorjani, B. Cantin, G.R. Dagenais P.J. Lupien and J.P. Despres, 1997. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation, 95: 69-75.
15. Malmstrom, R., C.J. Packard, M. Caslake, D. Bedford, P. Stewart, H. Yki-Jarvinen, J. Shepherd and M.R. Taskinen, 1997. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia, 40: 454-462.
16. NCEP., 1993. Summary of the Second Report of the National Cholesterol Education Program. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA., 269: 3015-3023.
17. Phillips, N.R., D. Waters and R.J. Havel, 1993. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation, 88: 2762-2770.
18. Sniderman, A.D., C. Wolfson, B. Teng, F.A. Franklin, P.S. Bachorik and P.O. Kwiterovich, 1982. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann. Intl. Med., 97: 833-839.
19. Sniderman, A.D., T. Scantlebury and K. Cianflone, 2001. Hypertriglyceridemic hyperapo B: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann. Intl. Med., 135: 447-459.
20. Stamler, J., O. Vaccaro, J.D. Neaton and D. Wentworth, 1993. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care, 16: 434-444.
21. Syvanne, M. and M.R. Taskinen, 1997. Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet, 350: SI 20-23.
22. Taskinen, M.R., 1990. Hyperlipidaemia in diabetes. Baillieres Clin. Endocrinol Metab., 4: 743-775.
23. Westerveld, H.T., J.E. Van Lennep, H.W. Van Lennep, A.H. Liem, J.A. De Boo, Y.T. Van der Schouw and D.W. Erkelens, 1998. Apolipoprotein B and coronary artery disease in women: A cross-sectional study in women undergoing their first coronary angiography. Arterioscler. Thromb. Vasc. Biol., 18: 1101-1107.
24. Whitney, E.N. and E.M. Hamilton, 1987. Understanding Nutrition, 4th Edn., West Publishing Company, pp: 248.
25. Young, S.G., 1990. Recent progress in understanding apolipoprotein B. Circulation, 82: 1574-1594.